Results 41 to 50 of about 10,024 (235)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

Viruses, 2022
Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses.
Ashley Jia Wen Yip, Zheng Yao Low, Vincent T. K. Chow, Sunil K. Lal   +3 more
doaj   +1 more source

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro [PDF]

, 2022
Introduction: The development of effective vaccines has partially mitigated the trend of the SARS-CoV-2 pandemic; however, the need for orally administered antiviral drugs persists.
Bastianelli, Sabrina, Busti, Chiara, Comez, Lucia, Francisci, Daniela, Gidari, Anna, Libera, Valeria, Macchiarulo, Antonio, Paciaroni, Alessandro, Pierucci, Sara, Sabbatini, Samuele, Schiaroli, Elisabetta, Vicenti, Ilaria, Zazzi, Maurizio   +12 more
core   +1 more source

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating.
Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico II COVID Team   +10 more
doaj   +1 more source

Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2 [PDF]

, 2022
Three directly acting antivirals (DAAs) demonstrated substantial reduction in COVID-19 hospitalizations and deaths in clinical trials. However, these agents did not completely prevent severe illness and are associated with cases of rebound illness and ...
Aittokallio, Tero, Biering, Scott B., Gale, Michael, Herring, Shawn, Hoffmann, Markus, Hsiang, Tien-Ying, Ianevski, Aleksandr, Poehlmann, Stefan, Polyak, Stephen J., Schiffer, Joshua T., Wagoner, Jessica, White, Judith M., Xu, Shuang   +12 more
core   +2 more sources

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model [PDF]

, 2021
BACKGROUND: Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently reported in COVID-19 patients.
Abdelnabi, R, Augustijns, P, Breuer, J, Chatterjee, AK, Coelmont, L, Dallmeier, K, De Jonghe, S, Do, TND, Foo, CS, Heylen, E, Jochmans, D, Kaptein, SJF, Langendries, L, Leyssen, P, Mols, R, Neyts, J, Pang, J, Vangeel, L, Vergote, V, Weynand, B, Williams, R, Zhang, X   +21 more
core   +1 more source

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

Antimicrobial Agents and Chemotherapy, 2021
Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a number of RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ...
W. Painter, W. Holman, J. Bush, F. Almazedi, H. Malik, N. Eraut, M. Morin, L. J. Szewczyk, G. Painter   +8 more
semanticscholar   +1 more source

Molnupiravir and Its Antiviral Activity Against COVID-19

Frontiers in Immunology, 2022
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden.
Lili Tian, Zehan Pang, Maochen Li, Fuxing Lou, Xiaoping An, Shaozhou Zhu, Lihua Song, Yigang Tong, Huahao Fan, Junfen Fan   +9 more
doaj   +1 more source

Molnupiravir; an effective drug in treating COVID-19? [PDF]

, 2021
n/
Alireza Pouramini, Fatemeh Kafi, Hamid Reza Jahantigh, Sanam Saeifar, Shakiba Hassanzadeh   +4 more
core   +2 more sources

Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis

Antibiotics, 2023
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is unknown. The goal of the current meta-analysis was to compare the real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 during the ...
Chienhsiu Huang, Tsung-Lung Lu, Lichen Lin   +2 more
doaj   +1 more source

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

Nature, 2023
Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus and
T. Sanderson, R. Hisner, I. Donovan-Banfield, H. Hartman, Alessandra Løchen, T. Peacock, Christopher Ruis   +6 more
semanticscholar   +1 more source